Mitralign Raises $24 Million

Mitralign Inc., a Tewksbury, Mass.-based developer of a catheter-based method for treating mitral regurgitation in patients suffering from congestive heart failure, has raised $24 million in Series C funding.

Medtronic and Johnson & Johnson Development Corp. co-led the round, and were joined by Oakwood Medical Investors, Palisade Capital Management and Accelerated Technology Partners. Return backers included Forbion, Giza Venture Capital, Oxford Biosciences and Triathlon Medical Venture Partners.

The company previously had raised around $28 million in VC funding.